ADMA Biologics, Inc.
ADMA · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $510M | $426M | +19.6% |
| Operating income | $191M | $139M | +37.7% |
| Net income | $147M | $198M | −25.7% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 4, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $141M | $134M | +5.1% |
| Operating income | $67.8M | $51.0M | +32.9% |
| Net income | $49.9M | $36.4M | +37.1% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was ADMA Biologics's revenue in FY2025?
- $510M in FY2025 (Fiscal year ended Dec 31, 2025), +19.6% vs $426M a year earlier, per its 10-K filed Feb 2026.
- Was ADMA Biologics profitable in FY2025?
- Yes: net income was $147M and operating income $191M in FY2025.
- What was ADMA Biologics's revenue in Q3 2026?
- $141M (+5.1% vs a year earlier), per its Form 10-Q filed Nov 4, 2026.